With the technical assistance of EUNICE ADDELSON BOSTON, MASSACHUSETTS T HE prothrombic activity of plasma, as measured by the one-stage method, decreases as plasma ages (x-3) because of deterioration of 'labile factor' necessary for the rapid conversion of prothrombin to thrombin by thromboplastin plus calcium. When, however, determinations are made by a modified procedure in which the test plasma is first diluted with pdkombin-free fresh plasma, the aged plasma shows iru;reased prothrombic activity (3). Similar observations have been recorded by others (4-6).
However, when determinations are made using fresh prothrombin-free plasma as diluent, prothrombic activity increases during storage at refrigerator temperature until the aged plasma becomes approximately two or three times as active as the original unstored plasma. Thereafter, the activity slowly declines. The 'hyperreactivity' is not demonstrable in plasma which ages at room or body temperatures. The interval of storage required for the development of increased prothrombic activity varies widely. In some instances the change becomes evident within 24 or 48 hours; in others, two weeks or more are necessary (table I) . When citrate (one part of 2.5 yO sodium citrate solution to 9 parts of blood) is used instead of oxalate as anticoagulant the appearance of hyperreactivity is delayed. Also, as has been observed previously by others (IO) and by us (3) , the decrease in whole plasma prothrombic activity is retarded.
DAYS STORED

Fig. LPROTHROMBIC ACTIVITY OF OXALATED HUMAN
PLASMA storedat$*-5*X Determinations made at intervals on the same plasma by the orthodox one-stage procedure on whole plasma (undiluted) and by the dilution technique (diluted) employing fresh BaSOd plasma as diluent.
Prothrombin can be adsorbed from plasma by BaSOd (9) . We have found that it can be eluted from this adsorbing agent by sodium citrate. The 'hyperreactive' prothrombin of stored plasma behaves similarly. When plasma is adsorbed at intervals during storage with 25 mg. BaSOd per cc. and the adsorbate eluted with sodium citrate, the prothrombic activities of the eluates parallel those of the unadsorbed parent plasma ( fig. 2 ). The supematants from the BaS04 adsorption show little or no activity u&*4* An eluate from the BaS04 adsorbate obtained from a 'hyperreactive' (166% of normal prothrombic activity) stored plasma exhibited only IO per cent prothrombic activity and contained 31.1 micrograms of nitrogen derived from I cc. of plasma (table 2) . However, when it was mixed with fresh plasma, the observed activity of the mixture was almost threefold the sum of the activities of the components. Separation thus of a plasma fraction, poor in prothrombin, yet capable of enhancing the prothrombic activity of fresh plasma to which it was added, indicates that the by 10.220.33.5 on April 18, 2017 http://ajplegacy.physiology.org/ Downloaded from 'hyperreactivity' which develops in stored plasma is due to the evolution of a prothrombin conversion accelerator and not to deterioration of an inhibitor.
Prothrombin-rich fractions derived from fresh plasma by BaS04 adsorption and citrate elution also show increasing activity ,during storage (table 3) . In constrast to some of the parent plasmas which were relatively slow in becoming hyperreactive the activity of the eluates increased within 24 hours (table I) . It should be noted that determinations on the eluates and the parent plasmas were made side by side, after both were adjusted to contain equal amounts of oxalate and citrate. The supernatants, very low in activity originally, remained unchanged. This indicated that the precursor of the accelerator which evolves during storage is adsorbed along with the prothrombin. It is possible that an accelerator might not be evident in the aged 'hypoprothrombinemic' plasma because its initial prothrombin content might be so small that an enhancement in activity might not be striking. Under such circumstances, addition of prothrombin in the form of fresh normal plasma or prothrombin-rich fractions should result in a greater prothrombic activity than would be expected on the basis of the added prothrombin alone. When prothrombin was thus added to the deprothrombinated stored plasma, no enhancement could be observed; the activity of these mixtures was equal to the sum of the activities of the components determined separately. When the prothrombin was only partially removed by adsorbing with smaller amounts of BaSOe, the 'hypoprothrombinemic' plasma (3&) of normal)
showed some rise in activity during storage ( fig. 3 ) although less than the whole parent plasma.
Dicumarol-induced hypoprothrombinemia was also studied. Three patients, treated with this drug for impending or actual myocardial infarction, had between 5 and 12 per cent prothrombin. During storage the plasmas of two showed some increase in activity, the earliest change appearing after 14 days (table 4) . However, when prothrombin was added in the manner described above, little, if any, further acceleration was demonstrable. Thus, plasma rendered markedly hypoprothrombinemic either by BaS04 adsorption or by dicumarol administration does not become strikingly 'hyperreactive' during storage or develop the ability to accelerate the conversion of added prothrombin. Similar results were obtained in a patient with hypoprothrombinemia due to severe hepatic cirrhosis (table 4) . It is not clear whether this is referable to reduction of prothrombin per se or to simultaneous inadequacy of a non-prothrombin precursor of the accelerator. There is evidence that dicumarol lowers, besides prothrombin, a substance which affects prothrombin conversion (I I, I 2). Also, the patient with liver disease seemed to be deficient not only in prothrombin but also in plasma factors important in prothrombin conversion since the prothrombic activity of her whole plasma (147~ of normal) was far less than that (33yo ) obtained with the dilution technique employing pro~~~ornbin-free normal plasma. Observations were also made on a S-week-old patient with congenital hypoprothrombinemia2 whose plasma prothrombic activity was I to 2 per cent of normal. During 6 days' storage it did not change appreciably nor did any accelerator evolve. Unfortunately, further observations could not be made since the patient died.
Platelets are not required for evolution of the accelerator. Normal oxalated plasma was rendered platelet-'freey3 by centrifugation for 15 minutes at ~5,000 rpm in a Type 2 international centrifuge with multi-speed attachment, kept in a constant 2 We are grateful to Dr. Charles A. Janeway, Physician-in-Chief of the Children's Hospital, Boston, for his cooperation in making this subject available for study. Details will be reported in a separate communication.
3 Counts made on the centrifuged plasma revealed 10,000 platelets or (pIatelet bodies' per cu. mm. of plasma. temperature room at 6*C. During storage the plasma developed increased prothrombic activity, parallel with the non-centrifuged plasma ( fig. 4) . The blood had been handled throughout in apparatus coated with silicone4 until the plasmas were placed in ordinary glass for storage. Also, the accelerator could be separated from the aged platelet-free plasma by BaSOd adsorption and subsequent elution. Furthermore, plasma from a patient with thrombocytopenic purpura secondary to acute leukemia (platelet count = 30,000 per cu. mm. of blood) became hyperreactive during storage.
That the platelets cannot, therefore, be implicated in evolution of the accelerator is in contrast to the interpretations of others (6, 14) who attributed the prothrombic hyperreactivity of stored plasma to the products of platelet lysis. The question also arises whether exposure to a 'foreign' surface is required.
Plasma derived from blood taken with siliconized apparatus and stored in siliconized Pooled oxalated plasma stored at 4O-5OC. for 14 days, then adsorbed with 25 mg. BaSC&/cc. The BaSQ was then eluted with 5% sodium citrate in 0.9% saline solution; final volume was that of original plasma.
1 Corrected for dilution of prothrombin mixture with prothrombin-free fresh plasma. 0 Eluate contained 31.x pg. N/CC. vessels becomes equally hyperreactive at the same time as plasma from the same individual handled throughout in ordinary glass. The prothrombin accelerator evolves also in stored hemophilic plasma. Of 5 hemophiliacs studied the plasmas from 2 showed increasing activity within 24 to 48 hours; in the others, a much longer time was required before any change was demonstrable. These phenomena could not be correlated with the clotting time of whole blood nor were they affected by accelerating coagulation with intravenous infusions of normal plasma (qo--180 cc.) before obtaining the hemophilic plasma for storage. On the theory that small amounts of thrombin, slowly evolved from prothrombin during storage, might be required for elaboration of the accelerator from an inert precursor (see later in discussion regarding conversion of plasma Ac-globulin to the serum type by thrombin) 0.1 and 0.2 units of thrombin (Parke, Davis topical thrombin) were added to 2.0 cc. of fresh chilled oxalated .hemophilic plasma which alone showed delayed increase in prothrombic activity upon aging. The addition of throm-bin did not accelerate the appearance of hyperreactivity. Small fibrin shreds and thin clots were observed in 24 hours, but the amount of fibrinogen thus removed had nu demonstrabIe tiuence on the prothrombin time.
DISCUSSfON
Changes in plasma prothrombic activity during storage have been studied by many workers. Non-uniformity of methods has led to divergent results and interpretations. Clearly the activity, as determined on whole plasma by the one-stage technique, declines after the first few days of storage, due to deterioration of a labile component which is present in fresh plasma (3) .
When determinations are made on mixtures of the stored, with prothrombin-free fresh, plasma, the activity i.s found to increase progressively until, at its height, it may be two or three times the initial value. Enhanced reactivity of fibrinogen to 1 On basis of normal plasma containing 100% prothrombic activity thrombin, one of the proposed explanations for this phenomenon (4), can be readily dismissed: the hyperreactivity of aged plasma is measured in a mixture in which go per cent or more of the clottable fibrinogen is provided by fresh prothrombin-free plasma. Furthermore, plasma fractions devoid of fibrinogen become hyperreactive during storage. Finally, we have found (IS) that stored plasma becomes less clottable by standard solutions of thrombin. Increasing prothrombic activity may reflect deterioration of an inhibitor such as an antiprothrombin, antithrombin or antithromboplastin. This explanation is also untenable since a prothrombin conversion accelerator can be separated from hyperreactive stored plasma.
Banfi ef al. (6) attribute the hyperreactivity of stored plasma to a prothrombin CSensitization,' whereby, under the influence of deteriorating platelets, prothrombin undergoes a molecular alteration yielding a product more rapidly convertible to thrombin by thromboplastin plus calcium. This interpretation, which resembles Bordet's (16) concept of proserozyme (less active prothrombin) being converted during coagulation to serozyme (more active prothrombin), can be excluded also by the fraction obtained from stored plasma, which was itself very low in prothrombic activity but, nevertheless, could markedly accelerate thrombin evolution from added prothrombin.
The prothrombic 'hyperreactivity' of stored plasma is best explained by slow elaboration of a factor which activates, accelerates or otherwise acts as an ancillary agent in the evolution of thrombin in the presence of thromboplastin plus calcium. Formation of similar substances has also been observed during blood coagulation (I 7, 18). Ware ef al, (I 7) have reported on swam AC-globulin which arises, under the influence of small amounts of thrombin, from a relatively inert precursor, pkasma AC-globulin. During storage slow conversion of prothrombin to thrombin may occur despite the presence of anticoagulant, thus providing the conditions necessary for transforming plasma AC-globulin into the serum type. It will be recalled, however, that the addition of small amounts of thrombin to hemophilic plasma failed to hasten the appearance of increased prothrombic activity.
Milstone (rs> described a prothrombin convertor, thrombokinase, which evolves from an inert precursor, prothrombokinase, during the first stage of coagulation. Calcium is required for the transformation; whether it can proceed in oxalated plasma is unknown. It is unlikely that the accelerator which evolves in stored plasma is thrombokinase because prothrombokinase is not adsorbed by BaS04 (19) whereas the precursor of the accelerator which evolves in stored plasma is adsorbed.
A prothrombin conversion accelerator which arises during coagulation has also been demonstrated in human serum by de Vries et al. (7) . It is relatively stable, in contrast to the extreme lability of AC-globulin in human serum (IO), can be adsorbed quantitatively by BaSOa or BaCOs and eluted by citrate solutions (zo), and it is greatly reduced in serum from hypoprothrombinemic blood? Its remarkable re- semblance in these respects to the accelerator which evolves in stored plasma suggests that as plasma ages very slow 'coagulation' occurs during which the 'serum' prothrombin conversion accelerator evolves. This would explain the deposition of fibrin clots during storage despite the presence of anticoagulant. That the accelerator cannot be detected by determinations on whde stored plasmas suggests that labile factor or some other plasma component similarly labile is necessary for its activity. During the first several weeks of storage, prothrombic activity, as measured by the orthodox one-stage technique, is the resultant of prothrombin concentration, unaltered labile factor and evolved prothrombin conversion accelerator. This must be considered in assays of labile factor based upon restoring prothrombic activity to stored plasma by adding fresh plasma or plasma fractions (5).
Progressive increase in the activity of aging prothrombin-rich plasma derivatives brings to mind the report of Ware and Seegers (22) on 'regeneration' of purified bovine prothrombin in the presence of thrombin. The question arises whether their observations are referable to evolution of a factor which favorably affects the yield as well as the velocity of thrombin formation. Changes in activity of prothrombin-rich fractions deserve careful consideration in the purification of prothrombin when guided by the one-stage technique. Also, prothrombin assays by the two-stage procedure must be viewed with caution until one can be sure that an accelerator evolving in a prothrombin fraction does not increase the yield of thrombin. In this connection there should be mentioned the recent observations of Lewis and Ferguson (23) that no limit is reached in the amount of thrombin obtained from a given quantity of purified prothrombin to which increasing amounts of AC-globulin are added.
Little can be said regarding the precursor of the accelerator, Platelets can be excluded by the experiments on thrombocytopenic plasma and on normal plasma stored in siliconized vessels. Our findings on plasma rendered prothrombin-deficient by dicumarol or by adsorption with BaS04 suggest that the plasma prothrombin concentration must be at least 30 per cent of normal before substantial amounts of the accelerator can evolve. However, this is probably not the sole requisite, as indicated by observations on the cirrhotic patient whose plasma, although it contained 30 to 40 per cent prothrombin, failed to become hyperreactive. This may have been related to the inadequacy of non-prothrombin factors important in the evolution of thrombin from prothrombin,7 which was observed in this subject.
Thus, two important changes in plasma clotting components have been demonstrated during storage: elaboration of an accelerator which favorably affects the velocity of prothrombin conversion, and deterioration of labile factor, which adversely influences this reaction. The question arises whether these phenomena are related. At first glance it appears that they are not since prothrombic hyperreactivity may appear in some instances before any deterioration of labile factor is detectable from determinations of the prothrombin time on whole plasma. However, as has already been mentioned the prothrombin time of plasma, at any point during storage, reflects the concentration of prothrombin, labile factor and the prothrombin conversion accelerator which evolves. Therefore, normal prothrombin time on the second, third or fourth day of storage does not necessarily exclude some deterioration of labile factor. Some loss in this component may have occurred, yet because of elaboration of some accelerator the prothrombin time need not be altered. Accordingly, deterioration of labile factor and evolution of the accelerator during storage may be interrelated.
It is also noteworthy that prothrombin hyperreactivity consequent to aging cannot be demonstrated unless a component found inf!e& plasma is simultaneously provided. This suggests that labile factor, or some other plasma substance sim larly labile, is essential for the activity of the accelerator in speeding thrombin evolution. The same is true of the prothrombin conversion accelerator found in serum (7) .
That the accelerator appears earlier in a prothrombin rich fraction than in the parent plasma suggests that its evolution may be retarded by the presence of one or more of the plasma proteins, or that the manipulation of fractionation may, somehow, render the precursor more susceptible to transformation.
r Insufficiency of plasma AC-globulin has been induced in dogs by injuring the liver with chloroform, resulting in an elevated prothrombin time (24) . 
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Why hypereactivity does not occur in plasma stored at room or body temperature in contrast to refrigerator temperature is obscure.
The prothrombic activity (one-stage) of normal plasma or prothrombin-rich fractions obtained by adsorption with BaS04 and elution with sodium citrate increases during storage at refrigerator temperature. This does not occur at room or body temperature. In some plasmas prothrombic hyperreactivity appears within 24 or 48 hours; in others it develops after two or more weeks of storage. ln the latter instances, prothrombinrich fractions become hyperreactive much earlier than the parent plasmas.
The phenomenon is attributable to evolution of an agent which accelerates the conversion of prothrombin to thrombin by thromboplastin plus calcium. The agent as well as its precursor(s) can, like prothrombin and the prothrombin conversion accelerator of serum, be adsorbed by BaSOa and eluted with sodium citrate. It arises in hemophilic plasma, thrombocytopenic plasma, and in normal plasma handled entirely in siliconized apparatus. The accelerator cannot be demonstrated in the absence of a labile factor present in fresh plasma.
Changes in stored dicumarolized plasma were not striking. Also, the accelerator did not evolve in plasma deprived of prothrombin by adsorption with BaSOd, or in hypoprothrombinemic plasma from a patient with severe hepatic cirrhosis. Its possible relationship to serum Ac-globulin, or the prothrombin conversion accelerator of serum, is discussed,
